CAS 26097-80-3|Cambendazol
| Common Name | Cambendazol | ||
|---|---|---|---|
| CAS Number | 26097-80-3 | Molecular Weight | 302.352 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C14H14N4O2S | Melting Point | 212-214℃ (ethyl acetate hexane ) |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS08 | Signal Word | Warning |
Names
| Name | propan-2-yl N-[2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-yl]carbamate |
|---|---|
| Synonym | More Synonyms |
Cambendazol BiologicalActivity
| Description | Cambendazole is one of the most effective agents for the therapy of human strongyloidiasis and [1]. |
|---|---|
| Related Catalog | Research Areas >>InfectionSignaling Pathways >>Others >>Others |
| References | [1]. Bicalho SA, et al. Cambendazole in the treatment of human strongyloidiasis. Am J Trop Med Hyg. 1983 Sep;32(5):1181-3. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Melting Point | 212-214℃ (ethyl acetate hexane ) |
| Molecular Formula | C14H14N4O2S |
| Molecular Weight | 302.352 |
| Exact Mass | 302.083740 |
| PSA | 108.14000 |
| LogP | 2.90 |
| Index of Refraction | 1.694 |
| InChIKey | QZWHWHNCPFEXLL-UHFFFAOYSA-N |
| SMILES | CC(C)OC(=O)Nc1ccc2nc(-c3cscn3)[nH]c2c1 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 80480 ug/kg
- SEX/DURATION :
- female 8-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 60400 ug/kg
- SEX/DURATION :
- female 8-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 60800 ug/kg
- SEX/DURATION :
- female 8-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 80800 ug/kg
- SEX/DURATION :
- female 8-15 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 348 mg/kg
- SEX/DURATION :
- female 6-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 348 mg/kg
- SEX/DURATION :
- female 6-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 75 mg/kg
- SEX/DURATION :
- female 21 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 75 mg/kg
- SEX/DURATION :
- female 21 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
MUTATION DATA - TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Mammal - domestic Leukocyte
- DOSE/DURATION :
- 1 mg/L
- REFERENCE :
- THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 31,505,1976
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Mammal - domestic Leukocyte
- DOSE/DURATION :
- 1 mg/L
- REFERENCE :
- THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 31,505,1976
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H361 |
| Precautionary Statements | P281 |
| Hazard Codes | Xn |
| Risk Phrases | 63 |
| Safety Phrases | 36/37 |
| RIDADR | NONH for all modes of transport |
| RTECS | DD6538000 |
Articles25
More Articles| The Hymenolepis diminuta-golden hamster (Mesocricetus auratus) model for the evaluation of gastrointestinal anticestode activity. J. Parasitol. 90(4) , 898-9, (2004) A novel laboratory anticestode assay was developed using Hymenolepis diminuta in the hamster. The commercial anticestode compounds, praziquantel, bunamidine, and niclosamide were active against patent... | |
| Structural requirements for the induction of cytochromes P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes. Biochem. Biophys. Res. Commun. 220(3) , 789-94, (1996) The effect of sulfur-containing benzimidazoles (thiabendazole, 5-hydroxy-thiabendazole, cambendazole) and sulfur-free derivatives (benzimidazole, carbendazim and 5-hydroxycarbendazim) on cytochrome P4... | |
| Controlled tests of activity of several antiparasitic compounds against natural infections of Haemonchus contortus and other helminths in lambs from a flock established in 1962. Am. J. Vet. Res. 54(3) , 406-10, (1993) Antiparasitic activity of several compounds was evaluated over a long period (about 25 years) in the same flock of sheep. Haemonchus contortus was of special interest, including its relation to drug r... |
Synonyms
| Cambenzole |
| Carbamic acid, N-[2-(4-thiazolyl)-1H-benzimidazol-6-yl]-, 1-methylethyl ester |
| Novazole |
| Isopropyl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate |
| Equiben |
| Camvet |
| (2-thiazol-4-yl-1(3)H-benzoimidazol-5-yl)-carbamic acid isopropyl ester |
| CBDZ |
| propan-2-yl [2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl]carbamate |
| cambendazole |
| Carbamic acid, (2-(4-thiazolyl)-1H-benzimidazol-5-yl)-, 1-methylethyl ester |
| Isopropyl 2-(4-thiazolyl)-5-benzimidazolecarbamate |
| NOE [French] |
| Noviben |
| Bonlam |
| [2-(4-thiazolyl)-1H-benzimidazol-5-yl]carbamic acid 1-methylethyl ester |
| 5-isopropoxycarbonylamino-2-(4'-thiazolyl)-benzimidazole |
| Camdan |
| Cambendazol |
